“It’s important to find safe and effective treatment options to improve the quality of life of these children, many of whom may be allergic to life,” said Wesley Burkes, a researcher at the University of North Carolina.
According to this North American study published in The Lancet magazine, which covers children between the ages of 0 and 3, this oral habit treatment allowed the removal of the allergen for two and a half years, up to five years in an older child.
Six months after the end of this long-term treatment, these children were able to tolerate a dose equivalent to 16 peanuts.
Moreover, for approximately three-quarters of the children, the treatment resulted in numbness, which is the plateau beneath the relief.
The dose was tolerated by the children when 16 peanuts were given immediately after treatment.
At the outset of the study, Stacy Jones, another researcher at the University of Arkansas Medical Sciences, said, “Children who went for relief were mostly in the younger group, and those under one year of age were getting better results.”
According to the scientist quoted in The Lancet, early intervention provides the best opportunity for relief.
“However, only a small number of children under the age of one participated in the study, so further research is needed,” he added.
Other studies already carried out point in the same direction, but this work stands alone for its duration.
The study found that 2% of children in Western countries are affected by peanut allergies.
These children should avoid eating these legumes and, in case of accidental exposure, should receive an injection of adrenaline to combat anaphylactic shock.
Without treatment, even the most sensitive children can be affected by indirect expressions such as the kiss of someone who has eaten peanuts.
The trial included 146 children aged 0 and 3 who were allergic to peanuts, 96 of whom received a daily dose of six peanut protein powders equivalent to six peanuts.
A further 50 children received oatmeal placebo to evaluate the effectiveness of the treatment.
The standard dose for measuring relief and depreciation is approximately 16 peanuts.
Twenty children in the treatment group received relief against one of the placebo group, while 68 people in the treatment group had numbness against one of the placebo group.
Although they could not tolerate the amount of 16 peanuts for relief, the other twenty children were able to tolerate the equivalent of six months and 12 peanuts after treatment.